Concepts (335)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Music | 3 | 2024 | 29 | 1.570 |
Why?
|
| Housing | 3 | 2024 | 68 | 1.450 |
Why?
|
| American Public Health Association | 2 | 2022 | 2 | 1.380 |
Why?
|
| Sequence Analysis, RNA | 1 | 2024 | 114 | 0.820 |
Why?
|
| Blood Vessel Prosthesis Implantation | 1 | 2023 | 6 | 0.810 |
Why?
|
| Computational Biology | 4 | 2024 | 324 | 0.800 |
Why?
|
| Aortic Aneurysm, Abdominal | 1 | 2023 | 19 | 0.800 |
Why?
|
| Zebrafish | 2 | 2021 | 146 | 0.780 |
Why?
|
| Atrial Fibrillation | 2 | 2025 | 121 | 0.770 |
Why?
|
| Single-Payer System | 1 | 2022 | 1 | 0.760 |
Why?
|
| Software | 1 | 2024 | 234 | 0.760 |
Why?
|
| Stroke | 3 | 2025 | 348 | 0.740 |
Why?
|
| Fundulidae | 2 | 2018 | 7 | 0.710 |
Why?
|
| Virus Diseases | 1 | 2021 | 27 | 0.700 |
Why?
|
| Uveal Neoplasms | 2 | 2019 | 11 | 0.670 |
Why?
|
| Gills | 2 | 2018 | 13 | 0.630 |
Why?
|
| Salinity | 2 | 2018 | 18 | 0.620 |
Why?
|
| Melanoma | 2 | 2019 | 109 | 0.610 |
Why?
|
| Public Policy | 1 | 2019 | 36 | 0.610 |
Why?
|
| Humans | 48 | 2025 | 42163 | 0.600 |
Why?
|
| Osmotic Pressure | 1 | 2018 | 22 | 0.590 |
Why?
|
| Cardiovascular Diseases | 1 | 2025 | 729 | 0.570 |
Why?
|
| MicroRNAs | 4 | 2018 | 501 | 0.570 |
Why?
|
| Arsenic | 2 | 2018 | 151 | 0.530 |
Why?
|
| Brachytherapy | 1 | 2016 | 11 | 0.530 |
Why?
|
| Depression | 1 | 2024 | 837 | 0.520 |
Why?
|
| Anticoagulants | 3 | 2025 | 121 | 0.520 |
Why?
|
| Anxiety | 1 | 2024 | 847 | 0.510 |
Why?
|
| Inflammation | 1 | 2021 | 729 | 0.480 |
Why?
|
| Gene Expression Regulation | 3 | 2018 | 1066 | 0.450 |
Why?
|
| Middle Aged | 18 | 2025 | 11819 | 0.410 |
Why?
|
| Aged, 80 and over | 10 | 2025 | 2803 | 0.400 |
Why?
|
| Aged | 17 | 2025 | 7982 | 0.400 |
Why?
|
| Adult | 15 | 2025 | 13458 | 0.370 |
Why?
|
| Female | 27 | 2025 | 24018 | 0.370 |
Why?
|
| Toxicogenetics | 3 | 2016 | 4 | 0.360 |
Why?
|
| Male | 26 | 2025 | 22779 | 0.360 |
Why?
|
| Hemorrhage | 2 | 2021 | 55 | 0.340 |
Why?
|
| Thrombosis | 2 | 2021 | 81 | 0.330 |
Why?
|
| Treatment Outcome | 4 | 2023 | 1586 | 0.300 |
Why?
|
| Risk Factors | 5 | 2025 | 3942 | 0.290 |
Why?
|
| Databases, Genetic | 3 | 2016 | 103 | 0.270 |
Why?
|
| Cause of Death | 2 | 2025 | 183 | 0.270 |
Why?
|
| Emergency Service, Hospital | 3 | 2017 | 268 | 0.260 |
Why?
|
| Fish Proteins | 2 | 2018 | 14 | 0.250 |
Why?
|
| Communicable Disease Control | 2 | 2023 | 38 | 0.250 |
Why?
|
| Retrospective Studies | 4 | 2023 | 2485 | 0.240 |
Why?
|
| Insurance Coverage | 2 | 2025 | 108 | 0.240 |
Why?
|
| Texas | 4 | 2025 | 428 | 0.230 |
Why?
|
| United States Environmental Protection Agency | 1 | 2025 | 6 | 0.230 |
Why?
|
| Power Plants | 1 | 2025 | 5 | 0.230 |
Why?
|
| Health Care Costs | 1 | 2025 | 89 | 0.220 |
Why?
|
| United States | 7 | 2025 | 5072 | 0.220 |
Why?
|
| Sparrows | 1 | 2024 | 4 | 0.220 |
Why?
|
| DNA | 2 | 2019 | 594 | 0.220 |
Why?
|
| src-Family Kinases | 1 | 2024 | 50 | 0.220 |
Why?
|
| Conserved Sequence | 1 | 2024 | 121 | 0.220 |
Why?
|
| Secondary Prevention | 2 | 2025 | 47 | 0.210 |
Why?
|
| DNA Transposable Elements | 1 | 2024 | 50 | 0.210 |
Why?
|
| Occupational Diseases | 1 | 2024 | 53 | 0.210 |
Why?
|
| Insurance, Health | 1 | 2025 | 143 | 0.210 |
Why?
|
| Data Collection | 1 | 2024 | 210 | 0.210 |
Why?
|
| Factor Analysis, Statistical | 1 | 2024 | 157 | 0.210 |
Why?
|
| Time Factors | 5 | 2025 | 1848 | 0.210 |
Why?
|
| Animals | 12 | 2024 | 16695 | 0.200 |
Why?
|
| Natriuretic Peptide, Brain | 1 | 2023 | 19 | 0.200 |
Why?
|
| Candidiasis, Vulvovaginal | 1 | 2023 | 10 | 0.200 |
Why?
|
| Aorta, Abdominal | 1 | 2023 | 17 | 0.200 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2024 | 159 | 0.200 |
Why?
|
| Radiation Oncology | 1 | 2022 | 2 | 0.200 |
Why?
|
| Mortality | 1 | 2024 | 174 | 0.200 |
Why?
|
| Gene Expression Regulation, Bacterial | 1 | 2024 | 168 | 0.200 |
Why?
|
| Morbidity | 1 | 2023 | 97 | 0.200 |
Why?
|
| Molecular Dynamics Simulation | 1 | 2024 | 183 | 0.190 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2024 | 187 | 0.190 |
Why?
|
| Coloring Agents | 1 | 2022 | 56 | 0.190 |
Why?
|
| Vulnerable Populations | 1 | 2024 | 163 | 0.190 |
Why?
|
| Insurance Carriers | 1 | 2022 | 2 | 0.190 |
Why?
|
| Kidney Diseases | 1 | 2024 | 170 | 0.190 |
Why?
|
| Health Care Reform | 1 | 2022 | 36 | 0.190 |
Why?
|
| Hematopoietic Stem Cells | 2 | 2020 | 47 | 0.180 |
Why?
|
| Young Adult | 6 | 2025 | 4936 | 0.180 |
Why?
|
| Age Factors | 1 | 2025 | 1139 | 0.180 |
Why?
|
| Factor Xa | 1 | 2021 | 4 | 0.180 |
Why?
|
| Urinary Tract Infections | 1 | 2021 | 42 | 0.180 |
Why?
|
| Infection Control | 1 | 2021 | 17 | 0.180 |
Why?
|
| Postoperative Complications | 1 | 2023 | 253 | 0.170 |
Why?
|
| Peptide Fragments | 1 | 2023 | 301 | 0.170 |
Why?
|
| Cultural Diversity | 1 | 2022 | 187 | 0.170 |
Why?
|
| Intracranial Hemorrhages | 1 | 2021 | 30 | 0.170 |
Why?
|
| Mental Disorders | 2 | 2018 | 377 | 0.170 |
Why?
|
| Clinical Trials as Topic | 1 | 2022 | 249 | 0.170 |
Why?
|
| Primary Health Care | 1 | 2024 | 362 | 0.170 |
Why?
|
| Alcoholism | 1 | 2024 | 292 | 0.170 |
Why?
|
| Physicians | 1 | 2023 | 180 | 0.170 |
Why?
|
| Attitude of Health Personnel | 1 | 2023 | 222 | 0.170 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2020 | 36 | 0.160 |
Why?
|
| Immunity, Innate | 1 | 2021 | 168 | 0.160 |
Why?
|
| Homeostasis | 1 | 2021 | 193 | 0.160 |
Why?
|
| Multicenter Studies as Topic | 1 | 2019 | 61 | 0.160 |
Why?
|
| Recombinant Proteins | 1 | 2021 | 522 | 0.160 |
Why?
|
| Human Rights | 1 | 2019 | 11 | 0.150 |
Why?
|
| Delivery of Health Care | 1 | 2022 | 309 | 0.150 |
Why?
|
| Prospective Studies | 5 | 2023 | 1574 | 0.150 |
Why?
|
| Disease | 2 | 2016 | 21 | 0.150 |
Why?
|
| Multidrug Resistance-Associated Proteins | 1 | 2019 | 47 | 0.150 |
Why?
|
| Ion Transport | 1 | 2018 | 22 | 0.150 |
Why?
|
| Body Height | 1 | 2019 | 53 | 0.150 |
Why?
|
| Quantitative Trait Loci | 1 | 2019 | 88 | 0.150 |
Why?
|
| Reproducibility of Results | 2 | 2019 | 1058 | 0.150 |
Why?
|
| Acclimatization | 1 | 2018 | 25 | 0.150 |
Why?
|
| Leukopoiesis | 1 | 2018 | 1 | 0.140 |
Why?
|
| School Health Services | 1 | 2019 | 89 | 0.140 |
Why?
|
| Follow-Up Studies | 2 | 2021 | 1051 | 0.140 |
Why?
|
| Chemokine CXCL12 | 1 | 2018 | 32 | 0.140 |
Why?
|
| Hydrocarbons | 1 | 2017 | 4 | 0.140 |
Why?
|
| Methane | 1 | 2017 | 10 | 0.140 |
Why?
|
| Stress, Psychological | 1 | 2024 | 641 | 0.140 |
Why?
|
| Metagenomics | 1 | 2017 | 43 | 0.140 |
Why?
|
| Leukocytes | 1 | 2018 | 79 | 0.140 |
Why?
|
| Receptors, CXCR4 | 1 | 2018 | 74 | 0.140 |
Why?
|
| Albuterol | 1 | 2017 | 10 | 0.140 |
Why?
|
| Nebulizers and Vaporizers | 1 | 2017 | 22 | 0.130 |
Why?
|
| Bronchodilator Agents | 1 | 2017 | 26 | 0.130 |
Why?
|
| Body Weight | 1 | 2019 | 428 | 0.130 |
Why?
|
| Neoplasm Staging | 2 | 2016 | 366 | 0.130 |
Why?
|
| Ecosystem | 1 | 2018 | 171 | 0.130 |
Why?
|
| Patient Satisfaction | 1 | 2018 | 163 | 0.130 |
Why?
|
| Sclera | 1 | 2016 | 6 | 0.130 |
Why?
|
| Uvea | 1 | 2016 | 4 | 0.130 |
Why?
|
| Evolution, Molecular | 2 | 2016 | 299 | 0.130 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2025 | 744 | 0.130 |
Why?
|
| Iodine Radioisotopes | 1 | 2016 | 39 | 0.130 |
Why?
|
| Dose-Response Relationship, Radiation | 1 | 2016 | 39 | 0.130 |
Why?
|
| Genome | 2 | 2016 | 149 | 0.130 |
Why?
|
| Psychometrics | 1 | 2019 | 350 | 0.130 |
Why?
|
| Brain Ischemia | 1 | 2019 | 196 | 0.130 |
Why?
|
| Search Engine | 1 | 2016 | 7 | 0.130 |
Why?
|
| Severity of Illness Index | 1 | 2019 | 708 | 0.130 |
Why?
|
| Tennessee | 1 | 2016 | 88 | 0.130 |
Why?
|
| Magnetic Resonance Imaging | 3 | 2019 | 577 | 0.130 |
Why?
|
| Mental Health Services | 1 | 2018 | 134 | 0.130 |
Why?
|
| Pilot Projects | 1 | 2019 | 733 | 0.130 |
Why?
|
| Water Pollutants, Chemical | 1 | 2018 | 170 | 0.130 |
Why?
|
| Chlorogenic Acid | 1 | 2016 | 1 | 0.130 |
Why?
|
| Ilex paraguariensis | 1 | 2016 | 5 | 0.120 |
Why?
|
| Visual Acuity | 1 | 2016 | 117 | 0.120 |
Why?
|
| Lymphatic Metastasis | 2 | 2006 | 81 | 0.120 |
Why?
|
| Antineoplastic Agents | 1 | 2024 | 979 | 0.120 |
Why?
|
| Survival Rate | 1 | 2016 | 353 | 0.120 |
Why?
|
| Length of Stay | 1 | 2017 | 231 | 0.120 |
Why?
|
| Vertebrates | 1 | 2015 | 33 | 0.120 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2016 | 150 | 0.120 |
Why?
|
| Phylogeny | 2 | 2018 | 740 | 0.120 |
Why?
|
| Contrast Media | 2 | 2006 | 101 | 0.120 |
Why?
|
| Models, Genetic | 1 | 2016 | 181 | 0.120 |
Why?
|
| Plant Leaves | 1 | 2016 | 134 | 0.120 |
Why?
|
| Oxides | 2 | 2006 | 97 | 0.120 |
Why?
|
| Mammals | 1 | 2016 | 109 | 0.120 |
Why?
|
| Phenotype | 4 | 2023 | 774 | 0.120 |
Why?
|
| Databases, Factual | 2 | 2013 | 336 | 0.110 |
Why?
|
| Lung Diseases | 1 | 2015 | 62 | 0.110 |
Why?
|
| Body Mass Index | 1 | 2019 | 916 | 0.110 |
Why?
|
| Placenta | 1 | 2016 | 113 | 0.110 |
Why?
|
| Gene Expression Profiling | 1 | 2018 | 683 | 0.110 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2019 | 860 | 0.110 |
Why?
|
| Iron | 2 | 2006 | 247 | 0.110 |
Why?
|
| Publications | 1 | 2013 | 10 | 0.110 |
Why?
|
| Data Mining | 1 | 2013 | 30 | 0.100 |
Why?
|
| Drug Industry | 1 | 2013 | 18 | 0.100 |
Why?
|
| Incidence | 1 | 2016 | 1054 | 0.100 |
Why?
|
| RNA | 1 | 2015 | 266 | 0.100 |
Why?
|
| Adaptation, Physiological | 1 | 2014 | 135 | 0.100 |
Why?
|
| Gene Regulatory Networks | 1 | 2014 | 143 | 0.100 |
Why?
|
| Asthma | 1 | 2017 | 410 | 0.100 |
Why?
|
| Alopecia Areata | 1 | 2012 | 4 | 0.100 |
Why?
|
| Neoplasms | 2 | 2022 | 1341 | 0.100 |
Why?
|
| Hair Follicle | 1 | 2012 | 10 | 0.100 |
Why?
|
| Retinoids | 1 | 2012 | 25 | 0.100 |
Why?
|
| Lung | 1 | 2015 | 484 | 0.100 |
Why?
|
| Pharmaceutical Preparations | 1 | 2013 | 93 | 0.090 |
Why?
|
| Patient Care Planning | 1 | 2011 | 18 | 0.090 |
Why?
|
| Cooperative Behavior | 1 | 2013 | 250 | 0.090 |
Why?
|
| Head Protective Devices | 1 | 2011 | 11 | 0.090 |
Why?
|
| Child | 5 | 2021 | 3381 | 0.090 |
Why?
|
| Craniocerebral Trauma | 1 | 2011 | 22 | 0.090 |
Why?
|
| Bicycling | 1 | 2011 | 19 | 0.090 |
Why?
|
| Mental Recall | 1 | 2011 | 81 | 0.090 |
Why?
|
| Purpura Fulminans | 1 | 2010 | 1 | 0.090 |
Why?
|
| Meningococcal Infections | 1 | 2010 | 4 | 0.090 |
Why?
|
| Peritonitis | 1 | 2010 | 11 | 0.090 |
Why?
|
| Neisseria meningitidis | 1 | 2010 | 17 | 0.080 |
Why?
|
| Crotalid Venoms | 1 | 2010 | 2 | 0.080 |
Why?
|
| Snake Bites | 1 | 2010 | 2 | 0.080 |
Why?
|
| Antivenins | 1 | 2010 | 4 | 0.080 |
Why?
|
| Adolescent | 5 | 2024 | 5950 | 0.080 |
Why?
|
| Brain Injuries | 1 | 2011 | 133 | 0.080 |
Why?
|
| ROC Curve | 3 | 2021 | 157 | 0.070 |
Why?
|
| Mice | 4 | 2024 | 6490 | 0.070 |
Why?
|
| Sensitivity and Specificity | 3 | 2021 | 602 | 0.070 |
Why?
|
| Alcohol Drinking | 1 | 2011 | 585 | 0.060 |
Why?
|
| Cytokines | 1 | 2010 | 661 | 0.060 |
Why?
|
| Cross-Sectional Studies | 3 | 2023 | 3077 | 0.060 |
Why?
|
| Seawater | 2 | 2017 | 53 | 0.060 |
Why?
|
| Lymph Nodes | 1 | 2006 | 73 | 0.060 |
Why?
|
| Greenhouse Effect | 1 | 2025 | 5 | 0.060 |
Why?
|
| Efficiency, Organizational | 1 | 2025 | 15 | 0.060 |
Why?
|
| Vietnam | 1 | 2025 | 61 | 0.060 |
Why?
|
| Acetamides | 1 | 2024 | 12 | 0.060 |
Why?
|
| Medically Uninsured | 1 | 2025 | 64 | 0.060 |
Why?
|
| Child, Preschool | 3 | 2017 | 1516 | 0.060 |
Why?
|
| Influenza A virus | 1 | 2024 | 31 | 0.050 |
Why?
|
| Morpholines | 1 | 2024 | 73 | 0.050 |
Why?
|
| Appointments and Schedules | 1 | 2024 | 27 | 0.050 |
Why?
|
| Benzamides | 1 | 2024 | 78 | 0.050 |
Why?
|
| Cost-Benefit Analysis | 1 | 2025 | 176 | 0.050 |
Why?
|
| Ambulatory Care Facilities | 1 | 2024 | 65 | 0.050 |
Why?
|
| Academic Medical Centers | 1 | 2024 | 73 | 0.050 |
Why?
|
| Head and Neck Neoplasms | 1 | 2024 | 81 | 0.050 |
Why?
|
| Pyridines | 1 | 2024 | 134 | 0.050 |
Why?
|
| Electronic Health Records | 1 | 2024 | 99 | 0.050 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2024 | 339 | 0.050 |
Why?
|
| Candida | 1 | 2023 | 41 | 0.050 |
Why?
|
| Esophageal Neoplasms | 1 | 2024 | 137 | 0.050 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2022 | 57 | 0.050 |
Why?
|
| Microscopy | 1 | 2022 | 33 | 0.050 |
Why?
|
| Public-Private Sector Partnerships | 1 | 2022 | 17 | 0.050 |
Why?
|
| Sequence Analysis, DNA | 1 | 2024 | 508 | 0.050 |
Why?
|
| Cell Communication | 1 | 2023 | 110 | 0.050 |
Why?
|
| Social Isolation | 1 | 2022 | 34 | 0.050 |
Why?
|
| Loneliness | 1 | 2022 | 22 | 0.050 |
Why?
|
| Urinalysis | 1 | 2021 | 34 | 0.050 |
Why?
|
| Fever | 1 | 2022 | 63 | 0.050 |
Why?
|
| Longitudinal Studies | 1 | 2025 | 1020 | 0.050 |
Why?
|
| Amino Acid Sequence | 1 | 2024 | 1188 | 0.050 |
Why?
|
| Candida albicans | 1 | 2023 | 173 | 0.040 |
Why?
|
| Antifungal Agents | 1 | 2023 | 169 | 0.040 |
Why?
|
| Single-Blind Method | 1 | 2021 | 53 | 0.040 |
Why?
|
| North America | 1 | 2021 | 85 | 0.040 |
Why?
|
| Europe | 1 | 2021 | 114 | 0.040 |
Why?
|
| Drug Administration Schedule | 1 | 2021 | 153 | 0.040 |
Why?
|
| Hematopoiesis | 1 | 2020 | 28 | 0.040 |
Why?
|
| Recurrence | 1 | 2021 | 149 | 0.040 |
Why?
|
| Prognosis | 1 | 2023 | 850 | 0.040 |
Why?
|
| Genomics | 1 | 2022 | 289 | 0.040 |
Why?
|
| Administration, Oral | 1 | 2021 | 256 | 0.040 |
Why?
|
| Health Personnel | 1 | 2023 | 262 | 0.040 |
Why?
|
| Tuberculosis | 1 | 2021 | 76 | 0.040 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2021 | 358 | 0.040 |
Why?
|
| Suicide | 1 | 2021 | 139 | 0.040 |
Why?
|
| Arterial Occlusive Diseases | 1 | 2019 | 6 | 0.040 |
Why?
|
| Pseudoxanthoma Elasticum | 1 | 2019 | 32 | 0.040 |
Why?
|
| Pain | 1 | 2022 | 283 | 0.040 |
Why?
|
| Veterans | 1 | 2021 | 203 | 0.040 |
Why?
|
| Health Services Accessibility | 1 | 2024 | 680 | 0.040 |
Why?
|
| Psychotropic Drugs | 1 | 2018 | 17 | 0.040 |
Why?
|
| Benzylamines | 1 | 2018 | 7 | 0.040 |
Why?
|
| Heterocyclic Compounds | 1 | 2018 | 23 | 0.040 |
Why?
|
| Gender Identity | 1 | 2019 | 117 | 0.040 |
Why?
|
| Quality of Life | 1 | 2023 | 599 | 0.040 |
Why?
|
| Signal Transduction | 2 | 2018 | 2111 | 0.040 |
Why?
|
| Deltaproteobacteria | 1 | 2017 | 8 | 0.030 |
Why?
|
| Gammaproteobacteria | 1 | 2017 | 7 | 0.030 |
Why?
|
| Archaea | 1 | 2017 | 17 | 0.030 |
Why?
|
| Risk Assessment | 1 | 2021 | 845 | 0.030 |
Why?
|
| Opioid-Related Disorders | 1 | 2021 | 188 | 0.030 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2019 | 170 | 0.030 |
Why?
|
| Minority Groups | 1 | 2022 | 663 | 0.030 |
Why?
|
| Counseling | 1 | 2018 | 134 | 0.030 |
Why?
|
| Cell Line, Tumor | 1 | 2024 | 2598 | 0.030 |
Why?
|
| Cell Differentiation | 1 | 2020 | 633 | 0.030 |
Why?
|
| Acute Disease | 1 | 2017 | 156 | 0.030 |
Why?
|
| Genotype | 1 | 2019 | 796 | 0.030 |
Why?
|
| Ferrosoferric Oxide | 2 | 2006 | 14 | 0.030 |
Why?
|
| Dextrans | 2 | 2006 | 28 | 0.030 |
Why?
|
| Quinic Acid | 1 | 2016 | 3 | 0.030 |
Why?
|
| Caffeic Acids | 1 | 2016 | 5 | 0.030 |
Why?
|
| User-Computer Interface | 1 | 2016 | 74 | 0.030 |
Why?
|
| Students | 1 | 2022 | 617 | 0.030 |
Why?
|
| Fossils | 1 | 2016 | 13 | 0.030 |
Why?
|
| Food Handling | 1 | 2016 | 35 | 0.030 |
Why?
|
| Mice, Knockout | 1 | 2019 | 1010 | 0.030 |
Why?
|
| Brazil | 1 | 2016 | 83 | 0.030 |
Why?
|
| Alu Elements | 1 | 2015 | 12 | 0.030 |
Why?
|
| Genetic Speciation | 1 | 2016 | 22 | 0.030 |
Why?
|
| Guanosine | 1 | 2015 | 28 | 0.030 |
Why?
|
| Adenine | 1 | 2015 | 48 | 0.030 |
Why?
|
| Adenosine Deaminase | 1 | 2015 | 21 | 0.030 |
Why?
|
| Terminology as Topic | 1 | 2015 | 40 | 0.030 |
Why?
|
| 3' Untranslated Regions | 1 | 2015 | 81 | 0.030 |
Why?
|
| Hot Temperature | 1 | 2016 | 141 | 0.030 |
Why?
|
| RNA Editing | 1 | 2015 | 37 | 0.030 |
Why?
|
| Mass Screening | 1 | 2019 | 531 | 0.030 |
Why?
|
| Salts | 1 | 2014 | 18 | 0.030 |
Why?
|
| Fresh Water | 1 | 2014 | 48 | 0.030 |
Why?
|
| Selection, Genetic | 1 | 2014 | 75 | 0.030 |
Why?
|
| Mice, Inbred C57BL | 1 | 2019 | 1804 | 0.030 |
Why?
|
| Disease Models, Animal | 1 | 2019 | 1554 | 0.030 |
Why?
|
| Chemokine CXCL9 | 1 | 2012 | 3 | 0.020 |
Why?
|
| Tissue Banks | 1 | 2012 | 9 | 0.020 |
Why?
|
| Granzymes | 1 | 2012 | 19 | 0.020 |
Why?
|
| Mice, Inbred C3H | 1 | 2012 | 80 | 0.020 |
Why?
|
| Interleukin-13 | 1 | 2012 | 20 | 0.020 |
Why?
|
| Chemokine CCL5 | 1 | 2012 | 40 | 0.020 |
Why?
|
| Animal Feed | 1 | 2012 | 50 | 0.020 |
Why?
|
| Vitamin A | 1 | 2012 | 85 | 0.020 |
Why?
|
| Biopsy | 1 | 2012 | 176 | 0.020 |
Why?
|
| Health Services Misuse | 1 | 2011 | 20 | 0.020 |
Why?
|
| Glasgow Coma Scale | 1 | 2011 | 23 | 0.020 |
Why?
|
| Radiography | 1 | 2011 | 72 | 0.020 |
Why?
|
| Interferon-gamma | 1 | 2012 | 268 | 0.020 |
Why?
|
| Statistics, Nonparametric | 1 | 2011 | 113 | 0.020 |
Why?
|
| Confidence Intervals | 1 | 2011 | 162 | 0.020 |
Why?
|
| Chi-Square Distribution | 1 | 2011 | 236 | 0.020 |
Why?
|
| Fatal Outcome | 1 | 2010 | 46 | 0.020 |
Why?
|
| Patient Discharge | 1 | 2011 | 131 | 0.020 |
Why?
|
| Pain Measurement | 1 | 2011 | 181 | 0.020 |
Why?
|
| Agkistrodon | 1 | 2010 | 1 | 0.020 |
Why?
|
| Crotalus | 1 | 2010 | 2 | 0.020 |
Why?
|
| Apolipoprotein C-III | 1 | 2010 | 7 | 0.020 |
Why?
|
| Plasminogen Activator Inhibitor 1 | 1 | 2010 | 23 | 0.020 |
Why?
|
| Pregnancy | 1 | 2016 | 1737 | 0.020 |
Why?
|
| Apolipoprotein A-I | 1 | 2010 | 24 | 0.020 |
Why?
|
| Epidermal Growth Factor | 1 | 2010 | 69 | 0.020 |
Why?
|
| Interleukin-4 | 1 | 2010 | 75 | 0.020 |
Why?
|
| Peroxidase | 1 | 2010 | 57 | 0.020 |
Why?
|
| Health Promotion | 1 | 2016 | 691 | 0.020 |
Why?
|
| Disease Progression | 1 | 2012 | 661 | 0.020 |
Why?
|
| Analysis of Variance | 1 | 2011 | 574 | 0.020 |
Why?
|
| Odds Ratio | 1 | 2011 | 587 | 0.020 |
Why?
|
| Skin | 1 | 2010 | 185 | 0.020 |
Why?
|
| HIV Infections | 1 | 2021 | 2535 | 0.020 |
Why?
|
| Rats | 1 | 2012 | 3701 | 0.010 |
Why?
|
| Predictive Value of Tests | 1 | 2006 | 438 | 0.010 |
Why?
|
| Nanoparticles | 1 | 2006 | 449 | 0.010 |
Why?
|